Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.

Preadmission use of benzodiazepines not neuroprotective

31 Jan 2019

Preadmission use of benzodiazepines does not appear to positively influence outcomes in patients with acute ischaemic stroke and could even contribute to increased poststroke mortality at 90 days, a study reports.

The prospective cohort study included 336 patients, among whom 62 (18.5 percent) were receiving benzodiazepines but not any other psychotropic drug when stroke occurred. Outcomes such as mortality, functional outcomes and cognition were evaluated at 8 and 90 days after stroke. Researchers applied propensity score methods to reduce the effects of potential confounding factors in the between-group comparisons.

Compared with nonusers, benzodiazepine users were older (73.1 vs 65.4 years; p=0.0002), more likely to be women (62.9 percent vs 42.7 percent; p=0.004), have arterial hypertension (77.4 percent vs 56.6 percent; p=0.002), lower body mass index (25.6 vs 27.0 kg/m2; p=0.042) and lower levels of alanine aminotransferase (18 vs 21 U/L; p=0.029). 

The mortality rate was markedly higher in benzodiazepine users vs nonusers both at day 8 (2.2 percent vs 8.1 percent; p=0.034) and day 90 (8.1 percent vs 25.9 percent; p=0.0001). However, only the difference in mortality rate at day 90 was of borderline of significance after controlling for baseline differences using propensity-score matching (odds ratio [OR], 3.93; 95 percent CI, 0.91–16.98). This difference remained significant with a similar treatment effect size in propensity score-adjusted cohort (adjusted OR, 3.50; 1.57–7.76).

In addition, more benzodiazepine users than nonusers had poor functional outcome at days 8 and 90, as defined by modified Rankin scale (mRS) ≥2 or by the Barthel index <95. Only the difference in mRS ≥2 at day 90 remained significant in propensity score-adjusted cohort (adjusted OR, 1.89; 1.02–3.48). Survivors at days 8 and 90 showed no significant difference in cognitive evaluation.

The present data do not support the putative neuroprotective effect of γ-aminobutyric acidA receptor agonists and should alert clinicians of their potential risks, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Mar 2018
Diagnosis of polycystic ovary syndrome (PCOS) is challenging, and there should be no rush to label an adolescent as having the condition before a thorough evaluation of symptoms, according to a leading endocrinologist who was speaking at the RCOG World Congress 2018 in Singapore.
Rachel Soon, 12 Dec 2018

A new ‘cooling’ drink product incorporating elements of traditional Chinese medicine (TCM) was launched in Kuala Lumpur recently.

06 Feb 2019
Depression symptoms in acne patients may improve following treatment with isotretinoin, according to a systematic review and meta-analysis.
Jairia Dela Cruz, 20 Dec 2017
The third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib affords better progression-free survival (PFS) than standard EFGR-TKIs in the first-line treatment of EGFR mutation–positive advanced nonsmall-cell lung cancer (NSCLC), with similar safety profile and lower serious adverse event rates, as reported in the phase III FLAURA trial.